Artiva Biotherapeutics to Cut Workforce by About 94%
Artiva Biotherapeutics is reducing its workforce by about 94% and evaluating strategic alternatives.
Story updates
11:34:23 AM UTC
SquawkNews
Artiva will discontinue AlloNK development after updated data and recent Grade 5 events, cut its workforce ~94%, and evaluate strategic alternatives including a sale or liquidation. Preliminary cash at Sep 30, 2026 was ~$319.1M (unaudited).Material DetailsContext by AI AnalystThis is a late-stage p…
12:01:13 PM UTC
SquawkNews
By Colin KellaherArtiva Biotherapeutics is shedding the bulk of its staff and putting itself up for sale after disappointing study results from lead development candidate AlloNK.Artiva on Tuesday said it is ending further work on AlloNK, including a planned Phase 3 study, after updated longer-term…